针对自:一种有前途的治疗策略,用于糖尿病和糖尿病病
Qi-Rui Li1, Hui-Ying Xu1, Rui-Ting Ma2
1School of Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Rd, Nanjing, 210023, China.
概括
自,一个细胞过程,与糖尿病 (DM) 和其脏并发症,糖尿病脏病 (DN) 密切相关. 调节自可能为这些疾病提供新的治疗策略.
科学领域:
- 细胞生物学 细胞生物学
- 内分泌学 在内分泌学.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 糖尿病 (DM) 因其并发症而显著影响生活质量和死亡率.
- 糖尿病病 (DN) 是糖尿病患者慢性病和功能衰竭的主要原因.
- 自是一种细胞降解过程,因其在DM和DN病理生理学中的作用越来越受认可.
研究的目的:
- 审查自和糖尿病 (DM) 之间的复杂关系,包括糖尿病病 (DN).
- 通过了解DM和DN中自的相互作用来探索新的治疗点和治疗方法.
- 调查自在脏平衡中的作用及其在DM和DN的发展和进展中的参与.
主要方法:
- 对调查糖尿病和糖尿病脏病的自性研究的文献综述.
- 对将自与DM和DN联系起来的病理生理机制的分析.
- 探索调节自的自然化合物,以获得潜在的治疗益处.
主要成果:
- 自在维持脏平衡中起着至关重要的作用.
- 自的失调与DM和DN的发展和进展有关.
- 自然化合物通过调节自来减轻DM和DN的潜力.
结论:
- 自和DM/DN之间的相互作用为治疗干预提供了有希望的途径.
- 准自途径可能会导致糖尿病并发症的新治疗方法.
- 对调节自的天然化合物的进一步研究是必要的,以控制糖尿病及其后果.
相关概念视频
Diabetes: Management and Pharmacotherapy
245
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
245
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


